mRNA |
PD-0325901 |
CCLE |
pan-cancer |
AAC |
-0.02 |
0.6 |
mRNA |
decitabine:carboplatin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.013 |
0.6 |
mRNA |
PRL-3 Inhibitor I |
CTRPv2 |
pan-cancer |
AAC |
-0.018 |
0.6 |
mRNA |
BRD-K03536150 |
CTRPv2 |
pan-cancer |
AAC |
-0.017 |
0.6 |
mRNA |
Doxorubicin |
FIMM |
pan-cancer |
AAC |
0.068 |
0.6 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.015 |
0.6 |
mRNA |
BRD-K13185470 |
CTRPv2 |
pan-cancer |
AAC |
-0.031 |
0.6 |
mRNA |
selumetinib:GDC-0941 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.016 |
0.6 |
mRNA |
lapatinib |
gCSI |
pan-cancer |
AAC |
0.024 |
0.6 |
mRNA |
PF-3758309 |
CTRPv2 |
pan-cancer |
AAC |
-0.02 |
0.7 |